The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER Drug Master File in Japan (CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER JDMF) empowers CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER JDMF during the approval evaluation for pharmaceutical products. At the time of CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER suppliers with JDMF on PharmaCompass.